Tick borne encephalitis vaccine is a Inactivated Vaccine owned by Pfizer, and is involved in 23 clinical trials, of which 22 were completed, and 1 is ongoing.
It contains sufficiently high concentration of anti-TBE antibody to provide protection against the TBE virus. It acts by inducing immune system of person.
The revenue for Tick borne encephalitis vaccine is expected to reach a total of $5.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tick borne encephalitis vaccine NPV Report.
Tick borne encephalitis vaccine was originated by Baxter International and is currently owned by Pfizer.
Tick borne encephalitis vaccine Overview
Tick-borne encephalitis virus (Ticovac, Fsme Immun) is a vaccine, which is used to prevent disease caused by Tick-Borne Encephalitis (TBE) Virus. It is formulated as injection suspension for intramuscular administration. It is indicated for the active (prophylactic) immunization of persons of 1 years of age and older against tick-borne encephalitis (TBE).
Vaccine is under development for the prevention of tick borne encephalitis.
Pfizer Overview
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.
Quick View – Tick borne encephalitis vaccine
| Report Segments |
|
| Drug Name |
|
| Administration Pathway |
|
| Therapeutic Areas |
|
| Key Companies |
|
| Highest Development Stage |
|
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
